Literature DB >> 1687508

The Mutual Assistance Programme of the IUATLD. Development, contribution and significance.

A Rouillon1.   

Abstract

The Mutual Assistance Programme of the IUATLD is aimed at trying to compensate for the neglect into which tuberculosis had fallen from the part of governments, teaching institutions and international agencies, and represents an innovative approach to promote solidarity between governments and voluntary organizations of low tuberculosis prevalence countries and those of high prevalence countries. The main objective has been to develop a system of delivery of treatment and diagnosis of tuberculosis that would be efficacious even under the difficult conditions of high prevalence of tuberculosis, low resources and/or socio-political disturbances. The system turned out not only to be efficacious in terms of cure rates and epidemiological impact but also to be efficient in terms of cost/benefit. The National Tuberculosis Programme's approach includes the application of short-course chemotherapy, the regular provision of drugs and products, a system of registers, forms and periodic reports, the assessment of the yield of case-finding and, most important of all, the analysis of the therapeutic results in successive cohorts of patients. Cure rates repeatedly reach around 85% in new cases and approximately 80% in retreatment cases, nationwide, in the countries where such programmes have been successively implemented. Each national programme has an important role of training and of capacity building. While serving the populations, the national programmes also provide the framework for relatively inexpensive operational research and, finally, the careful collection of data represents a basis--unique of its kind in the world--for the study of the clinical and epidemiological relationships between tuberculosis and HIV. The method has been endorsed by the WHO and has the support of the World Bank, the United Nations Development Plan and the main government Agencies for Development Cooperation. It is part of the new Global Strategy against Tuberculosis which is presently being developed under the WHO TB Unit. The other aspects of Mutual Assistance concern courses, consultation to programmes not directly sponsored by the IUATLD and publications.

Entities:  

Mesh:

Year:  1991        PMID: 1687508

Source DB:  PubMed          Journal:  Bull Int Union Tuberc Lung Dis        ISSN: 1011-789X


  5 in total

1.  Eliminating the category II retreatment regimen from national tuberculosis programme guidelines: the Georgian experience.

Authors:  Jennifer Furin; Medea Gegia; Carole Mitnick; Michael Rich; Sonya Shin; Mercedes Becerra; Peter Drobac; Paul Farmer; Rocio Hurtado; J Keith Joseph; Salmaan Keshavjee; Iagor Kalandadze
Journal:  Bull World Health Organ       Date:  2011-11-24       Impact factor: 9.408

2.  Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study.

Authors:  Edward C Jones-López; Irene Ayakaka; Jonathan Levin; Nancy Reilly; Francis Mumbowa; Scott Dryden-Peterson; Grace Nyakoojo; Kevin Fennelly; Beth Temple; Susan Nakubulwa; Moses L Joloba; Alphonse Okwera; Kathleen D Eisenach; Ruth McNerney; Alison M Elliott; Jerrold J Ellner; Peter G Smith; Roy D Mugerwa
Journal:  PLoS Med       Date:  2011-03-15       Impact factor: 11.069

3.  Tuberculosis chemotherapy in the 21 century: Back to the basics.

Authors:  Jyotsna M Joshi
Journal:  Lung India       Date:  2011-07

4.  Bridging implementation, knowledge, and ambition gaps to eliminate tuberculosis in the United States and globally.

Authors:  Kenneth G Castro; Philip LoBue
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

Review 5.  Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Sarah Royce; Pai Madhukar; William Burman; Andrew Vernon; Christian Lienhardt
Journal:  PLoS Med       Date:  2009-09       Impact factor: 11.069

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.